vs

Side-by-side financial comparison of AbCellera Biologics Inc. (ABCL) and Cryoport, Inc. (CYRX). Click either name above to swap in a different company.

Cryoport, Inc. is the larger business by last-quarter revenue ($45.5M vs $44.9M, roughly 1.0× AbCellera Biologics Inc.). Cryoport, Inc. runs the higher net margin — -17.5% vs -19.9%, a 2.4% gap on every dollar of revenue. On growth, AbCellera Biologics Inc. posted the faster year-over-year revenue change (788.4% vs 9.6%). Cryoport, Inc. produced more free cash flow last quarter ($-4.5M vs $-44.6M). Over the past eight quarters, AbCellera Biologics Inc.'s revenue compounded faster (112.3% CAGR vs 10.4%).

AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.

Cryoport, Inc. is a global provider of specialized temperature-controlled logistics and supply chain solutions focused on the life sciences, biopharmaceutical, and cell and gene therapy sectors. It partners with research institutions, biotech firms, and pharmaceutical manufacturers globally to support the safe transport of sensitive biological materials including clinical trial samples and advanced therapy products.

ABCL vs CYRX — Head-to-Head

Bigger by revenue
CYRX
CYRX
1.0× larger
CYRX
$45.5M
$44.9M
ABCL
Growing faster (revenue YoY)
ABCL
ABCL
+778.7% gap
ABCL
788.4%
9.6%
CYRX
Higher net margin
CYRX
CYRX
2.4% more per $
CYRX
-17.5%
-19.9%
ABCL
More free cash flow
CYRX
CYRX
$40.0M more FCF
CYRX
$-4.5M
$-44.6M
ABCL
Faster 2-yr revenue CAGR
ABCL
ABCL
Annualised
ABCL
112.3%
10.4%
CYRX

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ABCL
ABCL
CYRX
CYRX
Revenue
$44.9M
$45.5M
Net Profit
$-8.9M
$-8.0M
Gross Margin
47.8%
Operating Margin
-63.7%
-17.0%
Net Margin
-19.9%
-17.5%
Revenue YoY
788.4%
9.6%
Net Profit YoY
73.9%
57.4%
EPS (diluted)
$-0.03
$-0.19

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ABCL
ABCL
CYRX
CYRX
Q4 25
$44.9M
$45.5M
Q3 25
$9.0M
$44.2M
Q2 25
$17.1M
$45.5M
Q1 25
$4.2M
$41.0M
Q4 24
$5.0M
$41.5M
Q3 24
$6.5M
$38.3M
Q2 24
$7.3M
$39.7M
Q1 24
$10.0M
$37.3M
Net Profit
ABCL
ABCL
CYRX
CYRX
Q4 25
$-8.9M
$-8.0M
Q3 25
$-57.1M
$-6.9M
Q2 25
$-34.7M
$105.2M
Q1 25
$-45.6M
$-12.0M
Q4 24
$-18.7M
Q3 24
$-51.1M
$805.0K
Q2 24
$-36.9M
$-78.0M
Q1 24
$-40.6M
$-18.9M
Gross Margin
ABCL
ABCL
CYRX
CYRX
Q4 25
47.8%
Q3 25
48.2%
Q2 25
47.0%
Q1 25
45.4%
Q4 24
47.0%
Q3 24
45.5%
Q2 24
44.5%
Q1 24
40.4%
Operating Margin
ABCL
ABCL
CYRX
CYRX
Q4 25
-63.7%
-17.0%
Q3 25
-851.8%
-22.5%
Q2 25
-290.2%
-21.2%
Q1 25
-1479.6%
-23.1%
Q4 24
-30.7%
Q3 24
-1439.4%
-34.9%
Q2 24
-1276.2%
-196.5%
Q1 24
-551.5%
-46.9%
Net Margin
ABCL
ABCL
CYRX
CYRX
Q4 25
-19.9%
-17.5%
Q3 25
-637.8%
-15.7%
Q2 25
-203.3%
231.4%
Q1 25
-1077.2%
-29.2%
Q4 24
-45.1%
Q3 24
-785.4%
2.1%
Q2 24
-504.3%
-196.4%
Q1 24
-408.0%
-50.7%
EPS (diluted)
ABCL
ABCL
CYRX
CYRX
Q4 25
$-0.03
$-0.19
Q3 25
$-0.19
$-0.18
Q2 25
$-0.12
$2.05
Q1 25
$-0.15
$-0.28
Q4 24
$-0.42
Q3 24
$-0.17
$-0.02
Q2 24
$-0.13
$-1.62
Q1 24
$-0.14
$-0.43

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ABCL
ABCL
CYRX
CYRX
Cash + ST InvestmentsLiquidity on hand
$128.5M
$411.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$966.9M
$502.6M
Total Assets
$1.4B
$765.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ABCL
ABCL
CYRX
CYRX
Q4 25
$128.5M
$411.2M
Q3 25
$83.2M
$421.3M
Q2 25
$92.4M
$426.0M
Q1 25
$159.3M
$244.0M
Q4 24
$156.3M
$250.6M
Q3 24
$126.6M
$259.4M
Q2 24
$148.3M
$414.9M
Q1 24
$123.6M
$438.2M
Stockholders' Equity
ABCL
ABCL
CYRX
CYRX
Q4 25
$966.9M
$502.6M
Q3 25
$964.0M
$513.3M
Q2 25
$1.0B
$519.1M
Q1 25
$1.0B
$398.8M
Q4 24
$1.1B
$401.9M
Q3 24
$1.1B
$418.6M
Q2 24
$1.1B
$400.1M
Q1 24
$1.1B
$472.2M
Total Assets
ABCL
ABCL
CYRX
CYRX
Q4 25
$1.4B
$765.0M
Q3 25
$1.4B
$774.3M
Q2 25
$1.4B
$773.9M
Q1 25
$1.3B
$699.8M
Q4 24
$1.4B
$703.5M
Q3 24
$1.4B
$701.8M
Q2 24
$1.4B
$852.3M
Q1 24
$1.5B
$942.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ABCL
ABCL
CYRX
CYRX
Operating Cash FlowLast quarter
$-34.7M
$919.0K
Free Cash FlowOCF − Capex
$-44.6M
$-4.5M
FCF MarginFCF / Revenue
-99.4%
-10.0%
Capex IntensityCapex / Revenue
21.9%
12.0%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-174.1M
$-25.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ABCL
ABCL
CYRX
CYRX
Q4 25
$-34.7M
$919.0K
Q3 25
$-52.6M
$2.2M
Q2 25
$-32.4M
$-7.3M
Q1 25
$-11.6M
$-4.3M
Q4 24
$-108.6M
$-5.5M
Q3 24
$-28.9M
$447.0K
Q2 24
$-30.0M
$-8.0M
Q1 24
$-41.7M
$-3.3M
Free Cash Flow
ABCL
ABCL
CYRX
CYRX
Q4 25
$-44.6M
$-4.5M
Q3 25
$-61.5M
$-1.3M
Q2 25
$-45.8M
$-11.7M
Q1 25
$-22.2M
$-7.5M
Q4 24
$-187.0M
$-10.7M
Q3 24
$-47.4M
$-3.8M
Q2 24
$-50.1M
$-11.8M
Q1 24
$-65.8M
$-7.3M
FCF Margin
ABCL
ABCL
CYRX
CYRX
Q4 25
-99.4%
-10.0%
Q3 25
-687.0%
-2.9%
Q2 25
-267.9%
-25.7%
Q1 25
-524.0%
-18.3%
Q4 24
-3702.8%
-25.8%
Q3 24
-728.4%
-9.9%
Q2 24
-683.8%
-29.8%
Q1 24
-661.5%
-19.5%
Capex Intensity
ABCL
ABCL
CYRX
CYRX
Q4 25
21.9%
12.0%
Q3 25
99.7%
7.8%
Q2 25
78.2%
9.6%
Q1 25
251.1%
7.7%
Q4 24
1552.7%
12.6%
Q3 24
284.6%
11.1%
Q2 24
274.6%
9.5%
Q1 24
242.5%
10.7%
Cash Conversion
ABCL
ABCL
CYRX
CYRX
Q4 25
Q3 25
Q2 25
-0.07×
Q1 25
Q4 24
Q3 24
0.56×
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons